DRI Healthcare Reviews Rights as KalVista's Chiesi Acquisition Looms
Event summary
- DRI Healthcare holds royalty rights to Ekterly, a KalVista drug, via a royalty agreement.
- Chiesi Group's acquisition of KalVista may trigger a change of control under DRI's agreement.
- DRI is evaluating potential put options and buyback provisions tied to the deal.
- No decision has been made yet on whether DRI will exercise any rights.
The big picture
DRI Healthcare's response to KalVista's sale highlights the complexities of royalty agreements in biopharma M&A. The outcome could set a precedent for how financial stakeholders protect their interests in similar transactions. With over $3 billion deployed across 75+ royalties, DRI's move will be closely watched by other royalty monetization firms.
What we're watching
- Royalty Valuation
- How DRI Healthcare will value its Ekterly royalties in light of the acquisition.
- Put Option Exercise
- Whether DRI will exercise its put option, potentially forcing a buyout.
- Deal Completion
- The pace at which Chiesi finalizes the KalVista acquisition.
Related topics